Breath actuated Pressurized Inhaler Sales

Breath Actuated Pressurized Inhaler Sales Market Outlook

The global breath actuated pressurized inhaler sales market is anticipated to reach approximately USD 4 billion by 2033, growing at a robust compound annual growth rate (CAGR) of around 8% during the forecast period from 2025 to 2033. This growth is largely driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), which have become major global health concerns. Additionally, advancements in inhalation technology and a growing demand for more effective and user-friendly inhalation devices are further propelling market growth. The rising awareness of the importance of medication adherence among patients and the availability of a diverse range of inhaler options have become significant contributors to the market expansion. Moreover, the ongoing innovations in inhalation therapy and efforts to enhance patient convenience are expected to create fruitful opportunities for stakeholders involved in this market.

Growth Factor of the Market

The growth of the breath actuated pressurized inhaler sales market is influenced by several key factors. Firstly, the rising global burden of respiratory diseases is leading to a higher demand for efficient inhalation devices. The World Health Organization (WHO) indicates that respiratory conditions account for a significant chunk of the global disease burden, necessitating effective management options. Secondly, technological advancements are revolutionizing inhaler design, allowing for more precise dosing, better portability, and enhanced user experience. This evolution is driving both the healthcare providers and patients towards adopting modern inhalation solutions. Furthermore, the increasing elderly population and the prevalence of allergies are contributing to the demand for inhalers, as older adults often experience respiratory issues. Another vital aspect is the growing acceptance of online pharmacies, which facilitate easier access to inhalation devices and medications. Lastly, the rise in healthcare expenditure globally is likely to boost the market as more patients are able to afford specialized respiratory treatments.

Key Highlights of the Market

• Significant growth anticipated due to rising respiratory disease prevalence.
• Technological advancements leading to improved inhalation devices.
• Increasing online pharmacy presence enhancing accessibility.
• Global focus on patient adherence to medication management.
• Growing elderly population increasing demand for respiratory treatments.

By Product Type

Metered Dose Inhalers :

Metered Dose Inhalers (MDIs) are among the most commonly used inhalation devices, particularly for asthma and COPD management. These inhalers dispense a specific dose of medication in aerosol form, enabling direct delivery to the lungs. The compact and portable design of MDIs makes them convenient for patients, leading to their increased popularity. Moreover, advancements in formulation and propellant technology have enhanced the performance of MDIs, making them more effective and user-friendly. The ease of use and immediate response in medication delivery contribute to the growing demand for MDIs in the global market. Furthermore, the increasing awareness of asthma management guidelines that advocate the use of MDIs has fortified their market position.

Dry Powder Inhalers :

Dry Powder Inhalers (DPIs) are also gaining traction in the breath actuated inhaler sales market, particularly due to their ease of use and environmental benefits. Unlike MDIs, which require a propellant, DPIs rely on the patient's inhalation effort to disperse the medication. This characteristic allows for a more straightforward mechanism that many patients find easier to use. DPIs are associated with fewer side effects compared to traditional inhalers, as they deliver medication in a fine powder form, ensuring efficient deposition in the lungs. The growing trend towards device-free inhalation therapies and the demand for sustainable inhaler options contribute to the increasing acceptance of DPIs in the healthcare community.

Soft Mist Inhalers :

Soft Mist Inhalers (SMIs) represent a newer approach to inhalation therapy, offering a fine mist that enhances drug delivery to the lungs. The design of SMIs allows for a slower, softer release of aerosol, which minimizes throat deposition and maximizes lung absorption. This feature is particularly beneficial for patients who may struggle with the fast-acting nature of traditional MDIs. As a result, SMIs have gained a loyal following among patients looking for alternatives that enhance comfort during inhalation. The growth in awareness surrounding the effectiveness of SMIs in treating respiratory conditions is likely to further boost their market share.

Nebulizers :

Nebulizers are another critical category within the breath actuated inhaler sales market, typically used in clinical settings or home care environments. These devices convert liquid medication into a mist, allowing for easy inhalation. They are particularly useful for patients who may have difficulty using traditional inhalers, including young children and the elderly. The versatility of nebulizers in delivering various types of medications has made them a staple in respiratory therapy. The increased focus on home-based care solutions and the growing adoption of nebulizers for chronic conditions are expected to sustain their market demand.

Others :

The "Others" category of breath actuated inhalers includes a range of specialized devices that cater to unique patient needs or specific therapeutic applications. These may consist of adaptive inhalers, combination inhalers, or innovative delivery systems that target specific demographics or health conditions. The development of customized inhaler solutions is driven by the growing recognition of the need for patient-centric healthcare delivery. As healthcare providers continue to explore diverse inhalation methods, this segment is anticipated to witness steady growth, contributing to the overall dynamics of the inhaler market.

By Application

Asthma :

Asthma is a primary application driving the demand for breath actuated inhalers, owing to the chronic nature of the disease and the need for ongoing management. The increasing incidence of asthma worldwide, particularly in urban areas, has necessitated the development of effective inhalation therapies. Patients require reliable and easy-to-use inhalers to manage their symptoms effectively and improve their quality of life. Inhalers designed specifically for asthma treatment have been shown to reduce hospital visits, making them essential tools for both patients and healthcare providers. The emphasis on better asthma management and the availability of advanced inhalation devices are key factors propelling this application segment.

COPD :

Chronic Obstructive Pulmonary Disease (COPD) is another significant application area for breath actuated inhalers. With a substantial number of individuals affected worldwide, the need for effective inhalation therapies has never been more critical. COPD patients often require several medications for effective disease management, making the convenience of inhalers crucial. Technologies that enhance drug delivery, such as nebulizers and soft mist inhalers, are particularly popular among COPD patients who may have difficulty using traditional inhalers. The growing awareness around the need for better COPD management continues to fuel the demand for inhalers in this application segment.

Cystic Fibrosis :

Cystic Fibrosis (CF) is a genetic disorder that leads to severe respiratory complications. Inhalation therapy plays a significant role in managing CF, as it allows for targeted delivery of medications that can help clear mucus and improve lung function. The demand for specialized inhalation devices tailored for CF patients is increasing, driven by advancements in inhalation technology that enhance medication delivery. The focus on personalized medicine in CF treatment is leading to an uptick in the development of inhalers that meet the unique needs of these patients, fostering growth in this application segment.

Allergic Rhinitis :

Allergic rhinitis is another application area benefiting from breath actuated inhalers, particularly those delivering corticosteroids or antihistamines. Patients suffering from seasonal or perennial allergies often seek effective relief from symptoms such as nasal congestion and itching. The introduction of inhalers designed specifically for allergic rhinitis is increasing patient comfort and compliance with treatment regimens. The ease of use associated with inhalers is a significant advantage, allowing patients to manage their symptoms promptly and effectively. The growing awareness of allergic conditions and the importance of effective management strategies are expected to bolster the inhaler market within this application segment.

Others :

The "Others" application category encompasses various less common respiratory conditions and therapeutic approaches where breath actuated inhalers find utility. This segment includes applications for rare respiratory diseases and innovative treatment methods. As researchers explore new avenues for inhalation therapy, emerging applications are likely to drive growth in this segment. The ongoing exploration of inhaler use in conjunction with various treatment modalities presents opportunities for market expansion and innovation, contributing to the overall dynamics of the breath actuated inhaler sales market.

By Distribution Channel

Hospital Pharmacies :

Hospital pharmacies play a crucial role in the distribution of breath actuated inhalers, offering patients immediate access to necessary medications during their hospital stays. The presence of pharmacists in hospitals enables them to provide specialized advice on the proper use of inhalers, ensuring patient adherence and effective treatment. Furthermore, the collaboration between hospital pharmacies and healthcare providers allows for the timely dispensing of inhalers tailored to individual patient needs. As the focus on acute care management increases, hospital pharmacies are expected to continue being significant contributors to the inhaler sales market.

Retail Pharmacies :

Retail pharmacies are another vital distribution channel for breath actuated inhalers, providing patients with easy access to medications and devices. The widespread presence of retail pharmacies supports patient convenience, allowing individuals to purchase inhalers as needed. Pharmacists at retail locations also play a critical role in educating patients on proper inhaler usage and medication adherence. With the growing focus on community health and wellness, retail pharmacies are increasingly viewed as frontline healthcare resources, which is anticipated to drive sales of inhalers through this channel.

Online Pharmacies :

The rise of online pharmacies has transformed the distribution landscape for breath actuated inhalers, providing patients with the convenience of ordering medications from home. The accessibility of online pharmacies allows patients to discreetly purchase inhalers and related medications, particularly beneficial for those with chronic illnesses who require ongoing treatment. Additionally, many online pharmacies offer value-added services such as medication reminders and consultations, enhancing the overall patient experience. The increasing trend towards e-commerce in healthcare is likely to bolster the growth of inhaler sales through online channels.

Drug Stores :

Drug stores serve as an essential distribution channel for breath actuated inhalers, providing a wide variety of medications and health products. These stores offer convenience for patients seeking medications in their local communities, and often provide additional services such as consultations on medication management. Drug stores typically carry a diverse range of inhalers, catering to the needs of various patient demographics. As healthcare becomes more consumer-centric, the role of drug stores in facilitating access to inhalers is expected to grow, contributing to market expansion.

Others :

The "Others" category in the distribution channel segment encompasses alternative outlets such as specialty pharmacies and compounding pharmacies, which focus on individualized patient care. These unique distribution channels are particularly beneficial for patients who may require customized or compounded inhalation therapies. By offering personalized solutions, these pharmacies cater to niche markets that may not be adequately served by traditional channels, thus fostering growth in the inhaler sales market. As the demand for tailored healthcare solutions increases, the role of these alternative distribution channels is poised to grow significantly.

By Ingredient Type

Albuterol :

Albuterol is one of the most widely used ingredients in breath actuated inhalers, particularly for the management of asthma and COPD. It is a fast-acting bronchodilator that helps relieve symptoms such as wheezing, shortness of breath, and chest tightness. The effectiveness of albuterol in providing immediate relief has solidified its role as a critical component in inhalation therapies. As the prevalence of asthma continues to rise, the demand for albuterol-based inhalers is expected to grow, contributing significantly to the overall market.

Budesonide :

Budesonide is an inhaled corticosteroid that plays a vital role in the long-term management of asthma and COPD. This ingredient works by reducing inflammation in the airways, helping to prevent asthma attacks and improve overall lung function. The growing understanding of the benefits of corticosteroids in asthma management is likely to drive the demand for budesonide-containing inhalers. Additionally, the increasing emphasis on preventive care and chronic condition management in healthcare may further elevate the relevance of budesonide in inhalation products.

Formoterol :

Formoterol is a long-acting bronchodilator featured in many combination inhalers designed for the treatment of asthma and COPD. Its ability to provide sustained relief makes it an essential ingredient for patients requiring prolonged bronchodilation. The increasing awareness of the importance of combination therapies in managing chronic respiratory conditions is likely to bolster the demand for formoterol-containing inhalers. Patients seeking effective and convenient treatment options will continue to drive the market for formoterol-based inhalation products.

Fluticasone :

Fluticasone is another widely used corticosteroid in inhalation devices, known for its potency and effectiveness in reducing airway inflammation. It is often combined with long-acting bronchodilators to provide comprehensive asthma management. The growing focus on tailored therapeutic approaches in respiratory care is likely to enhance the market for fluticasone-based inhalers. As patients increasingly seek effective long-term management strategies, the relevance of fluticasone in inhalation therapy is anticipated to remain strong.

Others :

The "Others" category in ingredient types encompasses a variety of additional active ingredients used in breath actuated inhalers. These may include newer and emerging compounds that address specific patient needs or conditions. The ongoing research and development in inhalation therapies are likely to introduce innovative ingredient formulations that cater to niche markets. As the landscape of respiratory medications continues to evolve, this segment is expected to witness growth driven by advancements in pharmaceutical research and a focus on personalized medicine.

By Region

The regional analysis of the breath actuated pressurized inhaler sales market indicates substantial growth across various regions, with North America leading the way. In North America, the market is driven by a high prevalence of respiratory diseases, coupled with advanced healthcare infrastructure and increased spending on healthcare. The region is projected to hold over 35% of the global market share by 2033, with a CAGR of around 8.5% during the forecast period. This growth is supported by the rising number of asthma and COPD patients and the widespread availability of inhalation devices through various distribution channels.

In Europe, the breath actuated inhaler sales market is also witnessing considerable growth, driven by increased awareness of respiratory health and the rising incidence of respiratory diseases. New healthcare policies promoting better management of chronic conditions, along with an aging population, are significant factors that bolster market demand in the region. The European market is expected to contribute around 30% of the global sales, with a steady CAGR of approximately 7% during the forecast period. Meanwhile, the Asia Pacific region is on track for rapid growth, supported by increasing urbanization, pollution levels, and healthcare advancements, indicating a strong potential for market expansion in the coming years.

Opportunities

The breath actuated pressurized inhaler sales market presents numerous opportunities for growth and innovation in the coming years. One of the most significant opportunities lies in technological advancements that improve inhaler design and functionality. With the increasing focus on patient-centered healthcare, manufacturers can leverage smart inhaler technologies, such as digital connectivity and real-time monitoring, to enhance medication adherence and patient engagement. These innovations can significantly improve treatment outcomes for patients with chronic respiratory conditions. Furthermore, as the population ages, there will be a greater demand for inhalers that are easy to use, leading to potential collaborations between pharmaceutical companies and technology firms to develop user-friendly inhalation devices.

Another major opportunity is the rising demand for personalized medicine in respiratory care. Patients are increasingly seeking tailored treatment regimens that address their unique health needs, creating a market for customized inhalation therapies. This trend opens doors for the development of new formulations and inhaler types that cater to specific patient populations, such as children or those with comorbidities. Additionally, as awareness of respiratory conditions and their impact on quality of life grows, healthcare providers are more likely to advocate for inhalation therapy as a first-line treatment. This shift in perception can further expand the market, offering significant opportunities for companies invested in the development of innovative inhalation solutions.

Threats

While the breath actuated pressurized inhaler sales market holds promising growth potential, it also faces several threats that could impede its progress. One of the primary threats is the increasing competition from alternative therapeutic options for managing respiratory conditions, such as oral medications and targeted biologics. Patients may opt for these alternatives if they perceive them as more convenient or effective, potentially leading to decreased demand for inhalation-based therapies. Additionally, the market is subject to stringent regulatory requirements, which can pose challenges for new product development and market entry. Delays in regulatory approvals can hinder the speed at which new inhalation devices reach the market, impacting overall growth.

Another significant threat comes from the rising prevalence of counterfeit inhalation devices and medications. The proliferation of counterfeit products not only compromises patient safety but also undermines the credibility of legitimate brands within the inhaler market. As counterfeit products become more sophisticated, it becomes increasingly challenging for consumers to differentiate between genuine and fake products. This situation could lead to a decline in consumer trust and subsequently impact market sales. Moreover, fluctuations in raw material prices and supply chain disruptions can pose additional challenges for manufacturers, further complicating the competitive landscape of the breath actuated inhaler sales market.

Competitor Outlook

• GlaxoSmithKline
• Teva Pharmaceutical Industries
• Novartis International AG
• Boehringer Ingelheim
• Roche
• AstraZeneca
• Merck & Co.
• Pfizer Inc.
• Sun Pharmaceutical Industries
• Hikma Pharmaceuticals
• Mylan N.V.
• Chiesi Farmaceutici S.p.A.
• Otsuka Pharmaceutical
• Akorn, Inc.
• Indivior PLC

The competitive landscape of the breath actuated pressurized inhaler sales market is characterized by the presence of a diverse range of companies, each vying for market share through innovation and strategic partnerships. Major pharmaceutical companies such as GlaxoSmithKline and AstraZeneca dominate the market, boasting extensive portfolios of inhalation products tailored for various respiratory conditions. Their commitment to research and development has led to the introduction of advanced inhalation devices and combinations of medications that address specific patient needs. As these companies continue to invest in technological advancements, they are well-positioned to maintain their leadership in the market.

Teva Pharmaceutical Industries is another key player, recognized for its extensive range of generic inhalation products. The company’s focus on affordability and accessibility has made its inhalers popular among patients seeking cost-effective treatment options. Teva’s commitment to research also allows it to introduce innovative products, enabling it to compete effectively with branded offerings. Furthermore, Boehringer Ingelheim and Novartis International AG are notable competitors that leverage their strong research capabilities to enhance product efficacy and patient experience through their inhalation therapies, marking their significance in this competitive landscape.

Emerging companies are also making their mark in the breath actuated inhaler market, often focusing on niche segments or innovative technologies. These companies are gaining traction by developing smart inhalers that integrate digital health capabilities, providing patients with real-time monitoring and adherence support. The increasing interest in technology-driven healthcare solutions provides a unique opportunity for smaller firms to carve out a significant presence in the market. As a result, the competitive dynamics of the breath actuated pressurized inhaler sales market are expected to evolve, with both established and emerging players contributing to a vibrant and innovative landscape.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Roche
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Akorn, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AstraZeneca
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Merck & Co.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Indivior PLC
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 GlaxoSmithKline
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Boehringer Ingelheim
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hikma Pharmaceuticals
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Otsuka Pharmaceutical
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Novartis International AG
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Chiesi Farmaceutici S.p.A.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Breath actuated Pressurized Inhaler Sales Market, By Application
    • 6.1.1 Asthma
    • 6.1.2 COPD
    • 6.1.3 Cystic Fibrosis
    • 6.1.4 Allergic Rhinitis
    • 6.1.5 Others
  • 6.2 Breath actuated Pressurized Inhaler Sales Market, By Product Type
    • 6.2.1 Metered Dose Inhalers
    • 6.2.2 Dry Powder Inhalers
    • 6.2.3 Soft Mist Inhalers
    • 6.2.4 Nebulizers
    • 6.2.5 Others
  • 6.3 Breath actuated Pressurized Inhaler Sales Market, By Ingredient Type
    • 6.3.1 Albuterol
    • 6.3.2 Budesonide
    • 6.3.3 Formoterol
    • 6.3.4 Fluticasone
    • 6.3.5 Others
  • 6.4 Breath actuated Pressurized Inhaler Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Breath actuated Pressurized Inhaler Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Breath actuated Pressurized Inhaler Sales market is categorized based on

By Product Type

• Metered Dose Inhalers
• Dry Powder Inhalers
• Soft Mist Inhalers
• Nebulizers
• Others

By Application

• Asthma
• COPD
• Cystic Fibrosis
• Allergic Rhinitis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Albuterol
• Budesonide
• Formoterol
• Fluticasone
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• GlaxoSmithKline
• Teva Pharmaceutical Industries
• Novartis International AG
• Boehringer Ingelheim
• Roche
• AstraZeneca
• Merck & Co.
• Pfizer Inc.
• Sun Pharmaceutical Industries
• Hikma Pharmaceuticals
• Mylan N.V.
• Chiesi Farmaceutici S.p.A.
• Otsuka Pharmaceutical
• Akorn, Inc.
• Indivior PLC